Investment Analysts’ Recent Ratings Changes for Agios Pharmaceuticals (AGIO)

A number of research firms have changed their ratings and price targets for Agios Pharmaceuticals (NASDAQ: AGIO):

• 12/29/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/26/2025 – Agios Pharmaceuticals had its “buy” rating reaffirmed by analysts at Citigroup Inc..
• 12/26/2025 – Agios Pharmaceuticals had its price target raised by analysts at Leerink Partners from $34.00 to $40.00. They now have an “outperform” rating on the stock.
• 12/24/2025 – Agios Pharmaceuticals had its price target raised by analysts at HC Wainwright from $48.00 to $62.00. They now have a “buy” rating on the stock.
• 12/24/2025 – Agios Pharmaceuticals had its price target raised by analysts at Truist Financial Corporation from $32.00 to $38.00. They now have a “buy” rating on the stock.
• 12/24/2025 – Agios Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $32.00 to $34.00. They now have a “buy” rating on the stock.
• 12/22/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Agios Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $38.00 price target on the stock.
• 11/26/2025 – Agios Pharmaceuticals is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $38.00 price target on the stock.
• 11/25/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Agios Pharmaceuticals was given a new $32.00 price target on by analysts at Truist Financial Corporation.
• 11/24/2025 – Agios Pharmaceuticals is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $32.00 price target on the stock.
• 11/22/2025 – Agios Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/21/2025 – Agios Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $37.00 to $20.00. They now have a “neutral” rating on the stock.
• 11/20/2025 – Agios Pharmaceuticals was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
• 11/20/2025 – Agios Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $56.00 to $48.00. They now have a “buy” rating on the stock.
• 11/20/2025 – Agios Pharmaceuticals had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $40.00 to $25.00. They now have a “neutral” rating on the stock.
• 11/20/2025 – Agios Pharmaceuticals had its price target lowered by analysts at Bank of America Corporation from $54.00 to $32.00. They now have a “buy” rating on the stock.
• 11/20/2025 – Agios Pharmaceuticals was upgraded by analysts at Leerink Partners from a “market perform” rating to an “outperform” rating. They now have a $34.00 price target on the stock, down previously from $40.00.
• 11/19/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Agios Pharmaceuticals was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating. They now have a $28.00 price target on the stock, down previously from $57.00.
• 11/13/2025 – Agios Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Agios Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/7/2025 – Agios Pharmaceuticals was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d)” rating.
• 11/4/2025 – Agios Pharmaceuticals was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.

Insider Activity at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 3,302 shares of the company’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the completion of the transaction, the insider owned 61,727 shares of the company’s stock, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 3,902 shares of company stock valued at $170,754 over the last 90 days. 4.30% of the stock is owned by company insiders.

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.